SCHEMBL1787316

SCHEMBL1787316

Cc1ccc(-c2nn(NC(=O)Cc3cc(F)cc(F)c3)c(=O)c3ccccc23)cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.45
HPGD P15428 5/20 0.44
GLA P06280 1/20 0.42
HTT P42858 3/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
NR2F2 P24468 1/20 0.41
XBP1 P17861 2/20 0.41
USP2 O75604 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41
PKM P14618 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPK1 P28482 1/20 0.40
MMP1 P03956 1/20 0.40
MMP9 P14780 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30795123 1.00 SMN1; SMN2 (0.45) SMN1; SMN2HPGDGLAHTTPOLB
SCHEMBL30795119 0.90 RAB9A (0.50) SMN1; SMN2HPGDPOLBNPSR1ALDH1A1
SCHEMBL1789436 0.90 RAB9A (0.50) SMN1; SMN2HPGDPOLBNPSR1ALDH1A1
SCHEMBL1785673 0.89 MAPT (0.49) SMN1; SMN2HPGDPOLBTSHRUSP2
SCHEMBL30795077 0.89 MAPT (0.49) SMN1; SMN2HPGDPOLBTSHRUSP2
SCHEMBL30796353 0.87 MAPT (0.50) SMN1; SMN2HPGDPOLBTSHRUSP2
SCHEMBL1787537 0.87 MAPT (0.50) SMN1; SMN2HPGDPOLBTSHRUSP2
SCHEMBL30795092 0.86 ALDH1A1 (0.49) SMN1; SMN2HPGDHTTNPSR1ALDH1A1
SCHEMBL1790287 0.86 ALDH1A1 (0.49) SMN1; SMN2HPGDHTTNPSR1ALDH1A1
SCHEMBL30794712 0.86 LMNA (0.47) HTTPOLBNPSR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 US claimed
EP-2504317-A1 POTASSIUM CHANNEL MODULATORS Abbott Laboratories (US) 2012-10-03 EP claimed
WO-2011066168-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-06-03 WO claimed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 US claimed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 US disclosed
EP-2504317-A1 POTASSIUM CHANNEL MODULATORS Abbott Laboratories (US) 2012-10-03 EP disclosed
WO-2011066168-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-06-03 WO disclosed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNQ3 SMN1; SMN2 2070/4885HPGD 3401/4885GLA 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.